CJC-1295 + Ipamorelin Blend

CJC-1295 + Ipamorelin is one of the most commonly discussed growth-hormone (GH) secretagogue combinations. It pairs CJC-1295, a synthetic analog of growth-hormone-releasing hormone (GHRH), with Ipamorelin, a selective agonist of the ghrelin receptor (GHS-R1a). The rationale is that the two compounds act on distinct, complementary pituitary pathways, so combining them can produce a larger and more physiologic GH pulse than either alone. Importantly, "CJC-1295" refers to two different molecules in practice. The original peptide studied in humans (the DAC, or Drug Affinity Complex, version) binds serum albumin and has a multi-day half-life. The version most often paired with Ipamorelin in community use is CJC-1295 without DAC, also called Modified GRF (1-29), which has a half-life of roughly 30 minutes. Human trial data exist almost entirely for the DAC version of CJC-1295 and, separately, for early Ipamorelin pharmacology; controlled human trials of the specific combined blend are lacking. Direct human evidence for the stack as marketed is limited and largely extrapolated from single-compound studies plus anecdotal community reports. These products are sold for research use only and are not approved by the FDA for human therapeutic use outside of GH-deficiency contexts that use approved drugs. Claims around body composition, recovery, and anti-aging should be read as preliminary and evidence-graded rather than established outcomes.